This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

This study is currently recruiting participants.
See Contacts and Locations
Verified April 13, 2017 by National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )
ClinicalTrials.gov Identifier:
NCT03065335
First received: February 24, 2017
Last updated: June 7, 2017
Last verified: April 13, 2017
  Purpose

Background:

Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect.

Objective:

To study the effects of ketamine in treating depression.

Eligibility:

People ages 18-65 with major depressive disorder and healthy volunteers

Design:

Participants will be screened in another study, with:

  • Medical and psychiatric history
  • Psychiatric and physical exam
  • Blood, urine, and heart tests

Participants will be inpatients at NIH for 4 phases totaling 14-20 weeks.

Phase I (2-7 weeks):

  • Gradually stop current medications
  • MRI: Participants lie and perform tasks in a machine that takes pictures of the body.
  • Mood and thinking tests
  • Blood and urine tests
  • Sleep test: Monitors on the skin record brain waves, breathing, heart rate, and movement during sleep.
  • Transcranial magnetic stimulation: A coil on the scalp gives an electrical current that affects brain activity.
  • Stress tests: Electrodes on the skin measure reactions to loud noises or electric shocks.

Phase I tests are repeated in Phases II and III and in the final visit.

Phase II (4 5 weeks):

  • 4 weekly IV infusions of ketamine or a placebo during an MRI or MEG. For the MEG, a cone over the head records brain activity.

Phase III (optional):

  • 8 infusions of ketamine over 4 weeks

Phase IV (optional):

  • Symptoms monitoring for 4 weeks
  • Participants will have a final visit. They will be offered standard treatment at NIH for up to 2 months.

Condition Intervention Phase
Healthy Volunteer Major Depressive Disorder Depression Drug: Ketamine Other: Placebo Phase 1

National Institute of Mental Health (NIMH) has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.  

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ):

Primary Outcome Measures:
  • To demonstrate more robust neuropharmacodynamic effects measured by neuropharmacodynamic imaging (fMRI+EEG and MEG) of ketamine 0.5 mg/kg as compared to placebo administered over 40 minutes. [ Time Frame: baseline; w/ drug ]

Secondary Outcome Measures:
  • To determine if increases in synaptic plasticity, using electrophysiological measures in response to TMS and in association with sleep (i.e. slow wave sleep EEG activity) are associated with better antidepressant response to 0.5 mg/kg [ Time Frame: baseline and post-drug ]
  • To demonstrate enhanced efficacy, as measured by the MADRS, of IV ketamine 0.5 mg/kg in participants with MDD using a psychophysiological technique (i.e. NPU-threat test). [ Time Frame: baseline and post-drug ]
  • To identify baseline peripheral measures associated with response to the administration of ketamine 0.5 mg/kg, as potential biomarkers of acute (24 hour) treatment response. [ Time Frame: baseline and post-drug ]

Estimated Enrollment: 100
Actual Study Start Date: May 25, 2017
Estimated Study Completion Date: July 1, 2018
Estimated Primary Completion Date: July 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Phase II, Arm 2a
Double-blind, single dose of 0.5 mg/kg IV saline concurrently with MEG
Other: Placebo
0.5 mg/kg IV saline
Experimental: Phase II, Arm 1a
Double-blind, single dose of 0.5 mg/kg IV ketamine concurrently with MEG
Drug: Ketamine
N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
Experimental: Phase III
Double-blind, repeated dose of 0.5 mg/kg or 0.1 mg/kg IV ketamine
Drug: Ketamine
N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
No Intervention: Phase IV
Medication taper, drug-free period, and baseline assessments
No Intervention: Phase I
Medication taper, drug-free period, and baseline assessments
Placebo Comparator: Phase II, Arm 2b
Double-blind, single dose of 0.5 mg/kg IV saline, concurrently with fMRI+EEG
Other: Placebo
0.5 mg/kg IV saline
Experimental: Phase II Arm 1b
Double-blind, single dose of 0.5 mg/kg IV ketamine, concurrently with fMRI+EEG
Drug: Ketamine
N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Inclusion Criteria: All Subjects

  • 18 to 65 years of age.
  • Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document.
  • All subjects must have undergone a screening assessment under protocol 01-M-0254, The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers .
  • Agree to be hospitalized

Additional Inclusion Criteria: Patients with MDD

  • At the initial study enrollment, subjects must have fulfilled DSM-IV criteria for Major Depression, single episode or recurrent. Subjects must be experiencing a current major depressive episode of at least 2 weeks duration.
  • At the initial screening and beginning of Phases II and III, subjects must have a baseline score on the MADRS greater than or equal to 20 and YMRS of < 12.
  • Current or past history of lack of response to one adequate antidepressant trial, operationally defined using the Antidepressant Treatment History Form (ATHF); a failed adequate trial of ECT would count as an adequate antidepressant trial.

EXCLUSION CRITERIA:

Exclusion Criteria: All Subjects

  • Pregnant or nursing women or women who plan to become pregnant. Women who are able to get pregnant must be willing to use at least one form of effective birth control during the entire period of study participation (or until last clinical labs and rating) and have a negative pregnancy test that was obtained no more than 24 hours prior to MRI and infusion of ketamine.
  • Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
  • Clinically significant abnormal laboratory tests.
  • Subjects with one or more seizures without a clear and resolved etiology or current use of medication known to lower seizure threshold.
  • Treatment with any other concomitant medication 14 days prior to Phase II. An exception of this would be necessary for those who are taking Fluoxetine or Aripiprazole. Prior to Phase II, treatment with Fluoxetine must be discontinued for at least 5 weeks and treatment with Aripiprazole must be discontinued for at least 3 weeks.
  • Any use of opioid medication in the past 3 months
  • Presence of metallic (ferromagnetic) implants (e.g, heart pacemaker, aneurysm clip) (for subjects doing imaging component of the study only).
  • Presence of any medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications.
  • Subjects who have hearing loss that has been clinically evaluated and diagnosed
  • Participants who are uncomfortable in small closed spaces (have claustrophobia), unable to lie comfortably supine for up to 90 minutes, and would feel uncomfortable in the MRI machine (for subjects doing imaging component of the study only).
  • Positive HIV test
  • Weight > 119 kg
  • A current NIMH employee/staff or their immediate family member

Additional Exclusion Criteria: Patients with MDD

  • Current diagnosis of Bipolar Disorder including Bipolar I, Bipolar II, or Bipolar NOS diagnoses.
  • Current psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV.
  • Subjects with a history of DSM-IV drug or alcohol dependency or abuse (except for caffeine or nicotine dependence) within the preceding 3 months. In addition, subjects who currently are using drugs (except for caffeine or nicotine) must not have used illicit substances or known drugs of abuse in the 2 weeks prior to screen and must have a negative alcohol and drug urine test (except for prescribed benzodiazepines or stimulants) urine test at screening.
  • Treatment with a reversible MAOI within two weeks prior to Phase II.
  • Subjects who, in the investigator s judgment, pose a current serious suicidal or homicidal risk.

Additional Exclusion Criteria: Healthy Volunteers

  • Current or past history of any DSM-IV Axis I disorder based on clinical assessment and confirmed by a structured diagnostic interview (SCID).
  • First-degree relative with a history of any DSM-IV Axis I disorder.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03065335

Contacts
Contact: Libby Jolkovsky (877) 646-3644 libby_jolkovsky@nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
Investigators
Principal Investigator: Carlos A Zarate, M.D. National Institute of Mental Health (NIMH)
  More Information

Additional Information:
Responsible Party: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT03065335     History of Changes
Other Study ID Numbers: 170060
17-M-0060
Study First Received: February 24, 2017
Last Updated: June 7, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ):
Magnetic Resonance Imaging
Magnetoencephalography
Major Depressive Disorder
Ketamine
NEUROPHARMACOLOGY

Additional relevant MeSH terms:
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Ketamine
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 27, 2017